Nautilus Biotechnology (NAUT) Equity Average (2020 - 2026)
Nautilus Biotechnology has reported Equity Average over the past 7 years, most recently at $150.7 million for Q1 2026.
- Quarterly results put Equity Average at $150.7 million for Q1 2026, down 25.24% from a year ago — trailing twelve months through Mar 2026 was $150.7 million (down 25.24% YoY), and the annual figure for FY2025 was $182.9 million, down 22.86%.
- Equity Average reached $150.7 million in Q1 2026 per NAUT's latest filing, down from $163.1 million in the prior quarter.
- Across five years, Equity Average topped out at $356.6 million in Q1 2022 and bottomed at $150.7 million in Q1 2026.
- Median Equity Average over the past 5 years was $257.4 million (2024), compared with a mean of $255.1 million.
- The largest annual shift saw Equity Average skyrocketed 1172.35% in 2022 before it dropped 25.24% in 2026.
- Over 5 years, Equity Average stood at $320.1 million in 2022, then decreased by 15.25% to $271.3 million in 2023, then decreased by 20.36% to $216.1 million in 2024, then fell by 24.54% to $163.1 million in 2025, then dropped by 7.58% to $150.7 million in 2026.
- Business Quant data shows Equity Average for NAUT at $150.7 million in Q1 2026, $163.1 million in Q4 2025, and $175.1 million in Q3 2025.